We are a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of coronaviruses (including SARS-CoV-2), influenza viruses, noroviruses and hepatitis C viruses. We employ a unique structure-based drug discovery technology platform and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs.

We are leveraging our core competencies and decade of experience in antiviral therapeutics to combat pandemic and seasonal influenza and the global COVID-19 health crisis. Given the growing global need for an effective, safe antiviral treatment, we are advancing multiple antiviral therapeutic candidates as quickly and efficiently as possible, while also advancing the discovery and development of antiviral compounds for other high-value indications.

Media

Cocrystal Pharma Discusses Clinical Progress and Significance of Its Novel Antiviral Therapeutics Pipeline with The Stock Day Podcast

January 23, 2023

Cocrystal Pharma Partners With hVIVO in New Antiviral Flu Treatment Phase 2 Trial

IDSE Infectious Disease Special Edition

August 8, 2022

Cocrystal Antiviral Flu Candidate Shows Potential for Once-Daily Treatment in Phase 1 Trial

IDSE Infectious Disease Special Edition

July 22, 2022

Life Science Leader

CoCrystal's Co-Ceos

June 6, 2022

Cocrystal, NIAID expand partnership for Covid-19 protease inhibitors Pharmaceutical Technology

June 2, 2022

Empowered Patient Podcast with Karen Jagoda

Drug Development Platform Creating Novel Antiviral Therapeutics for Pandemics and Seasonal Influenza with Sam Lee and Jim Martin Cocrystal Pharma

May 8, 2022

Cocrystal Pharma advancing programs in high-value antiviral drug targets

BioTuesday.com

April 4, 2022

Cocrystal’s Proprietary Technologies in Antiviral Therapeutics to Combat COVID-19

October 11, 2021

C-Suite Interview with Cocrystal Pharma (COCP) Interim Co-CEOs Sam Lee, President & James Martin, CFO

June 9, 2021

Media

Cocrystal Pharma Discusses Clinical Progress and Significance of Its Novel Antiviral Therapeutics Pipeline with The Stock Day Podcast

Cocrystal Pharma Partners With hVIVO in New Antiviral Flu Treatment Phase 2 Trial

Cocrystal Antiviral Flu Candidate Shows Potential for Once-Daily Treatment in Phase 1 Trial

Life Science Leader

Cocrystal, NIAID expand partnership for Covid-19 protease inhibitors Pharmaceutical Technology

Empowered Patient Podcast with Karen Jagoda

Cocrystal Pharma advancing programs in high-value antiviral drug targets

Cocrystal’s Proprietary Technologies in Antiviral Therapeutics to Combat COVID-19

C-Suite Interview with Cocrystal Pharma (COCP) Interim Co-CEOs Sam Lee, President & James Martin, CFO

Nasdaq Facebook Live Interview

Nasdaq Bell Ringing Ceremony

Cocrystal Overview

Cocrystal Technology Overview

Sign Up for Email Alerts